Biolidics said on that it has partnered with Japanese diagnostics firm Sysmex on the development of a liquid biopsy-based cancer test for the Asian market.

The companies have been collaborating since 2016 on a liquid biopsy system that combines Biolidics’ ClearCell FX1 automated label-free circulating tumor cell separation and enrichment platform with Sysmex’s MI-FCM molecular imaging flow cytometer system.

Under the terms of their latest agreement, the companies will jointly develop a laboratory-developed test based on their respective technologies. Following clinical validation by Biolidics affiliate SAM Laboratory, Biolidics — formerly known as Clearbridge BioMedics — will commercialize the test in Asian markets outside of Japan.

Additional terms were not disclosed.

Source: https://www.genomeweb.com/